Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Stable stage of chronic obstructive pulmonary disease, Tele-home rehabilitation, randomized controlled trial
Brief summary
This study aims to evaluate the clinical efficacy of breath-guided improvement of COPD exercise ability, establish a breath-guided rehabilitation program of intelligent iot and remote home, improve COPD exercise ability, reduce acute exacerbation, and form high-quality clinical evidence.
Detailed description
Chronic obstructive pulmonary disease (COPD) is the most common chronic airway disease in China. Based on the digital management platform, 548 patients with COPD in stable stage were selected as the research objects. A multi-center, randomized, controlled clinical trial design was adopted to scientifically evaluate the clinical efficacy of breath-guided improvement of COPD exercise ability and reveal its mechanism of action. A breath-guided rehabilitation program based on intelligent iot and remote home was established and promoted to improve exercise ability and reduce acute exacerbation. To form high-quality clinical evidence, and realize tracking management, real-time evaluation and effect evaluation throughout rehabilitation.
Interventions
BEHAVIORALBreathing guided exercise
Breathing guided exercise are divided into six sections: relaxing standing, two fields breathing, regulating lung and kidney, turning side finger, running kidney hall and nourishing qi and collecting gong. Exercise time: 5 days a week, 1 to 2 times a day, a total of 24 weeks.
BEHAVIORALFlat walking training
Flat walking training can be performed either outdoors or on flat indoor surfaces at a steady pace of 80 to 120 steps per minute for at least 30 minutes each session, raising the heart rate to the target range and maintaining it for over 10 minutes. This should be done 3 to 5 times a week, with 1 to 2 sessions each day, for a total of 24 weeks. The intensity of the exercise is moderate. The target heart rate based on heart rate reserve is calculated as (maximum heart rate during exercise - resting heart rate) × (40-60)% + resting heart rate.
Sponsors
Shanxi Bethune Hospital
Henan Fantasy Intelligent Technology Co., Ltd
Henan University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with COPD in stable stage * Patients with grade 2 to 4 lung function * Age 40\ 80 years old * Be able to use smart phones, computers and other devices independently or with the help of family members during home training * Volunteer for treatment and sign an informed consent form
Exclusion criteria
* Pregnant or lactating women and patients with recent pregnancy plans * Delirious, dementia, all kinds of mental illness * Tumor patients who have undergone resection, radiation, and chemotherapy within 5 years * Patients with severe osteoarthropathy or osteoporosis, unstable fractures * Patients with severe visual impairment that cannot be improved or who have epilepsy or vertigo and cannot use VR devices * Patients with progressive neuromuscular disease * Patients with pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism and other pulmonary diseases * Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.) * Patients with severe liver disease (cirrhosis, portal hypertension and bleeding caused by esophageal and gastric varices, etc.) and severe kidney disease (dialysis, kidney transplantation, etc.) * Participants who were participating in other clinical trials within 1 month prior to enrollment * People who stay in bed for a long time for various reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 6 Minutes Walking Distance Test (6MWD) | Changes in baseline 6MWD test at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The 6-minute walking distance of the two groups was calculated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Degree of breathing difficulty | Changes in baseline mMRC scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The modified Medical Research Council dyspnoea scale (mMRC) will be used to assess severity of dyspnea. The mMRC scale is a 4-point (0-4) scale. 0 means no dyspnea perception, 4 means severe dyspnea perception. |
| Borg dyspnea score | Changes in baseline Borg dyspnea score at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | Borg dyspnea score is a 10-point (0-10) scale based on the severity of dyspnoea. 0 means no dyspnea perception, 10 means most severe dyspnea perception. |
| The COPD Assessment Test(CAT) | Changes in baseline CAT scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The COPD Assessment Test (CAT) is an 8-item questionnaire that assesses health status in patients with COPD. The questionnaire uses a 0-5 point scale, with higher values indicating a greater impact of COPD on the patient. |
| Lung function | Changes in baseline Lung function test at weeks 0 and 24 of the treatment. | Forced Vital Capacity (FVC)、Forced Expiratory Volume in One Second (FEV1) and Percentage of Forced Expiratory Volume in One Second to Predicted Value (FEV1% pred) were mainly used for lung function evaluation. |
| Anxiety Scale | Changes in baseline SAS scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The Self-Rating Anxiety Scale (SAS) was used to assess the anxiety state of patients. It is a questionnaire consisting of 20 items, with a score range of 1 to 4. The higher the value, the more severe the anxiety state of the patients. |
| Incidence of acute exacerbation | Changes in baseline Incidence of acute exacerbation at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The proportion of patients with ≥1 acute exacerbation in each group during the study period was recorded. If the interval between two acute exacerbations was within 5 days, it was considered as 1 acute exacerbation. |
| Clinical symptom assessment questionnaire (CCQ) | Changes in baseline CCQ scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The Clinical symptom assessment questionnaire (CCQ) is a self-administered questionnaire that measures healthrelated quality of life. It is an 10-item questionnaire on a 0-6 point scale with higher values indicating greater impact of COPD. |
| St. George's Respiratory Questionnaire (SGRQ) | Changes in baseline SGRQ scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The St. George's Respiratory Questionnaire (SGRQ) scores will be used to evaluate quality of life with a total score of 0-100. The higher scores will indicate the worse outcomes. |
| The modified Effectiveness Satisfaction Questionnaire for COPD (mESQ-COPD) | Changes in baseline mESQ-COPD scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The modified Effectiveness Satisfaction Questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction. The mESQ-COPD contains 19 items in four domains. mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction. |
| The modified COPD Patient-Reported Outcome scale (mCOPD-PRO) | Changes in baseline mCOPD-PRO scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The modified COPD Patient-Reported Outcome scale (mCOPD-PRO) will be used to assess quality of life. The mCOPD-PRO contains 27 items in three domains. mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status. |
| Depression Scale | Changes in baseline SDS scores at weeks 12 and 24 of the treatment period and at 28 weeks of follow-up. | The Self-Rating Depression Scale (SDS) was used to assess the depressive state of patients. It is a questionnaire consisting of 20 items, with a score range of 1 to 4. The higher the value, the more severe the depressive state of the patients. |
Countries
China
Contacts
Primary ContactHailong Zhang, doctor
Backup ContactJiansheng Li, doctor
Outcome results
None listed